Antidepressant “Black Box” Warning For Pediatric Suicidality Risk Recommended
This article was originally published in The Pink Sheet Daily
Executive Summary
“Black box” warning would encourage discussion of risks and benefits of antidepressant therapy in children by physicians, FDA advisory committee members say. Warning likely to affect direct-to-consumer advertising, FDA notes. Committee members recommend class warning for all antidepressants, including new products.
You may also be interested in...
Adult SSRI Use And Suicidality To Get FDA Advisory Committee Review, J&J Says
A committee will meet within the next few months to review selective serotonin reuptake inhibitors and suicidality in adults, J&J Senior VP Waldstreicher says. The company’s NDA for the SSRI dapoxetine is pending; J&J is seeking to differentiate the premature ejaculation agent from the rest of the class.
Adult SSRI Use And Suicidality To Get FDA Advisory Committee Review, J&J Says
A committee will meet within the next few months to review selective serotonin reuptake inhibitors and suicidality in adults, J&J Senior VP Waldstreicher says. The company’s NDA for the SSRI dapoxetine is pending; J&J is seeking to differentiate the premature ejaculation agent from the rest of the class.
Antidepressant DTC Ads Must Disclose New Risk Information Within 30 Days
Antidepressant manufacturers have 30 days to bring their direct-to consumer ads into compliance following FDA's approval of a "black box" class warning